Journal of Cystic Fibrosis
Volume 9, Issue 4 , Pages 292-295 , July 2010

Serum tobramycin levels following delivery of tobramycin (Tobi®) via eFlow® advanced nebuliser in children with cystic fibrosis

  • E.L. Guy

      Affiliations

    • Leeds Regional Paediatric Cystic Fibrosis Centre, St James's University Hospital, Leeds, LS9 7TF, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 113 2065200; fax: +44 113 2067011.
    • ,
  • M. Bosomworth

      Affiliations

    • Department of Biochemistry, St James's University Hospital, Leeds LS9 7TF, United Kingdom
    • ,
  • M. Denton

      Affiliations

    • Department of Microbiology, St James's University Hospital, Leeds LS9 7TF, United Kingdom
    • ,
  • S.P. Conway

      Affiliations

    • Leeds Regional Paediatric Cystic Fibrosis Centre, St James's University Hospital, Leeds, LS9 7TF, United Kingdom
    • ,
  • K.G. Brownlee

      Affiliations

    • Leeds Regional Paediatric Cystic Fibrosis Centre, St James's University Hospital, Leeds, LS9 7TF, United Kingdom
    • ,
  • T.W.R. Lee

      Affiliations

    • Leeds Regional Paediatric Cystic Fibrosis Centre, St James's University Hospital, Leeds, LS9 7TF, United Kingdom

Received 8 December 2009 ,Revised 2 March 2010 ,Accepted 15 March 2010.

References 

  1. Koch C, Hoiby N. Pathogenesis of cystic fibrosis. Lancet. 1993;341(8852):1065–1069
  2. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, et al. Risk factors for rate of decline in FEV1 in children and adolescents with cystic fibrosis. J Pediatr. 2007;151:134–139
  3. Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol. 2001;32:277–287
  4. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. NEJM. 1999;340:23–30
  5. Wiesemann HG, SteinKamp G, Ratjen F, Bauernfeind A, Przyklenk B, Döring G, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Pediatr Pulmonol. 1998;25:88–92
  6. Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Syst. Rev. 2006;(1):
  7. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-Pseudomonal antibiotics for cystic fibrosis. Cochrane Database of Syst. Rev. 2003;(2):
  8. Moss RB. Long term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 2002;121:55–63
  9. Heijerman H, Westerman E, Conway S, Touw D, Döring G. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J of Cyst Fibros. 2009;8(5):295–315For the consensus working group
  10. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol. 2005;39(1):15–20
  11. Mulheran M. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Chemotherapy. 2001;45(9):2502–2509
  12. Etherington C, Bosomworth M, Clifton I, Peckham DG, Conway SP. Measurement of urinary N-acetyl-b-d-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics. J of Cyst Fibros. 2007;6:67–73
  13. Pai VB, Nahata MC. Efficacy and safety of aerosolized tobramycin in cystic fibrosis. Pediatr Pulmonol. 2001;32:314–327
  14. Geller D, Rosenfeld M, Waltz DA, Wilmott RW. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest. 2003;123:28–36
  15. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002;122:219–226
  16. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, et al. Cystic fibrosis therapeutics development network study group. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003;167:841–849
  17. Hubert D, Leroy S, Nove-Josserand R, Murris-Espin M, Mely L, Dominique S, et al. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow® rapid nebulizer in cystic fibrosis. J of Cyst Fibros. 2009;8(5):332–337
  18. Lass JS, Sant A, Knoch M. New advances in aerosolised drug delivery: vibrating membrane nebuliser technology. Expert Opin Drug Deliv. 2006;3(5):693–702
  19. Rosenfeld M, Gibson R, McNamara S, Emerson J, McCoyd KS, Shell R, et al. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J Pediatr. 2001;139:572–577
  20. Patatanian L. Inhaled tobramycin-associated hearing loss in an adolescent with renal failure. Pediatr Infect Dis J. 2006;25(3):276–278
  21. Yuen C-T, Price RG, Chattagoon L, Richardson AC, Praill PFG. Colourimetric assays for N-Acetyl-β-d-glucosaminidase and β-D-galactosidase in human urine using newly-developed β-nitrosyryl substrates. Clin Chim Acta. 1982;124:195–204
  22. Novartis TOBI prescribing information, July 2008; http://www.pharma.us.novartis.com/product/pi/pdf/tobi.pdf, accessed 29.10.09.
  23. Ring E, Eber E, Erwa W, Zach MS. Urinary N-acetyl-beta-d-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation. Arch Dis Child. 1998;78:540–543

☆ The title has been presented as a poster at the 32nd European Cystic Fibrosis Conference, 10–13th June 2009, Brest, France.

PII: S1569-1993(10)00034-2

doi: 10.1016/j.jcf.2010.03.007

Journal of Cystic Fibrosis
Volume 9, Issue 4 , Pages 292-295 , July 2010

Article Tools